PDCD1 and cancer: Immune checkpoint inhibitor (ICI) therapy, especially for the blockade of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) interactions, has fundamentally revolutionized the treatment of various cancers, including CRC [2–4].